Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial - PubMed
4 hours ago
- #Clinical Trial
- #Insulin Therapy
- #Diabetes
- Phase 2 trial comparing once-weekly insulin GZR4 with once-daily insulin degludec in Chinese people with type 2 diabetes.
- Two cohorts studied: insulin-naïve (Cohort A) and previously basal insulin-treated (Cohort B).
- Primary outcome was change in HbA1c from baseline to week 16.
- GZR4 showed similar HbA1c reduction to insulin degludec in Cohort A (-1.50 vs -1.48 percentage points).
- Greater HbA1c reduction with GZR4 in Cohort B (-1.26 vs -0.87 percentage points).
- Similar proportions of participants achieved HbA1c targets in both groups at week 16.
- No significant difference in treatment-emergent adverse events between groups.
- Slightly higher incidence of hypoglycemia (mostly level 1) with GZR4, especially in Cohort B.
- No severe hypoglycemia reported in either group.
- Findings support further investigation in phase 3 trials with adjusted GZR4 dosing.